BIO Asia 2009 - Reimbursement in Japan

Registration is now closed. Visit us at the Grand Hyatt Tokyo to register on-site.

To help prepare for BIO Asia 2009, BIO and BioCentury have teamed up to provide BIO-Asia pre-registrants free access to BCIQ: BioCentury Online intelligence.

BCIQ's Company, Financial and Pipeline Analyst modules allow you to easily access BioCentury's industry knowledge of more than 4,500 private and public companies, $225 billion in financings, and 6,000 biopharma products.

Co-Host

Lead Sponsor

BIO Double Helix Sponsors

BIO Helix Sponsors

Conference Sponsors

With support from

Reimbursement in Japan

Monday, January 19, 2009
3:15 pm - 4:30 pm
Tarragon Room

Reimbursement for innovative therapeutics is a key component for investors and companies in terms of evaluating returns and opportunities for investment. For example, the pricing practices that the Japanese government has instituted are leading to greater adoption of generics and [also questions about the use of proprietary named-therapies versus their generic equivalents]. This panel will discuss trends in reimbursement, an assessment of how investors are considering these changes and companies’ approaches to these issues.

Moderator:

Dr. Ludwig Kanzler, Associate Principal, McKinsey & Company, Inc., Japan

Panelists:

Elizabeth Cobbs, Senior Director, Public and Industry Policy, Banyu Pharmaceuticals
Aleks Engel, VP International Strategy & Business Development, Baxter Asia Pacific
Koichi Kawabuchi, Professor of Health Economics, Tokyo Medical and Dental University
Noriatsu Kono, Technical Officer, Economics Bureau, Japan Ministry of Health, Labor and Welfare